VK2735 for Weight Management Phase 2

Summary

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.

Timeline

Start

2023-08-31

Primary completion

2024-02-27

Completion

2024-04-02

Outcome

Met primary endpoint

paper CONCLUSIONS: All subcutaneous doses of VK2735 significantly reduced body weight. PMID 41508550 ↗

release “The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints” vikingtherapeutics.com ↗

release “The VENTURE trial successfully achieved its primary endpoint and all secondary endpoints” vikingtherapeutics.com ↗

release “The VENTURE trial successfully achieved its primary and all secondary endpoints, with patients receiving VK2735 demonstrating clinically meaningful reductions in body weight compared with placebo.” vikingtherapeutics.com ↗

release “Phase 2 VENTURE study of VK2735 in obesity. This trial successfully achieved its primary and secondary endpoints” vikingtherapeutics.com ↗

release “In 2024, Viking announced positive results from the Phase 2 VENTURE study of VK2735 in obesity. This trial successfully achieved its primary and secondary endpoints.” vikingtherapeutics.com ↗

Publications

• Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, Ji S, Stubbe S, Hedges P, Lian B. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026 Mar;34(3):537-549. doi: 10.1002/oby.70106. Epub 2026 Jan 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VK2735	Peptide	2.5 mg	Subcutaneous
Subject	VK2735	Peptide	15 mg	Subcutaneous

Indications

No indication recorded.